Brisse B, Bender F, Gülker H, Niehues H
Z Kardiol. 1978 Sep;67(9):609-11.
In 9 patients with tachyarrhythmia and atrial fibrillation the effect of the i.v. application of the calcium antagonist Ro 11-1781 on the av-conduction was investigated. All patients received 1 mg/kg during 2-3 minutes. A significant decrease of the ventricular rate at the end of the injection period was noted. The maximal decrease of the av-conduction of 10-32 % of the initial ventricular rate was observed 5-10 min after the injection. During 60 min the initial heart rate before application of the drug was not yet reached again. The registrations prove the inihibiting effect of Ro 11-1781 on av-conduction in atrial fibrillation, which was sufficient for therapeutic use in our cases concerning the reduction of heart rate and duration of the effect. No serious side effects were observed.
在9例快速心律失常和心房颤动患者中，研究了静脉应用钙拮抗剂Ro 11-1781对房室传导的影响。所有患者在2至3分钟内接受1mg/kg药物。注射期结束时心室率显著下降。注射后5至10分钟观察到房室传导最大下降幅度为初始心室率的10%至32%。在60分钟内，未再次达到用药前的初始心率。记录结果证明Ro 11-1781对心房颤动时的房室传导有抑制作用，在我们的病例中，该作用足以用于降低心率和延长作用持续时间的治疗。未观察到严重副作用。
